| Dissolution and Relative Bio-availability of Bio-Co-Enzyme Q10 purum |
| Currently available Coenzyme Q10 dosage forms exhibit negligible dissolution indicating potentially poor bioavailability. In order to improve its dissolution profile and thereby its absorption. |
| A new process was employed to
produce Bio-Coenzyme Q10 purum . This novel isolate in the form of a waxy crystalline
powder or soft mass is encoupled with the respective enzymes EC:1.6.5.3 and made suitable for soft gelatin capsule
(encapsulation) which can passed the USP Dissolution requirement for nutritional
supplements. When compared with other commercially available dosage forms for relative
bioavailability in human subjects, Bio-Coenzyme Q10 purum was found to be vastly superior
(a 6 fold increase in plasma CoQ10 values over baseline, and up to 300% greater relative
bioavailability over other dosage forms tested). Coenzyme Q10 (Ubiquinone) is a lipid-soluble compound found in the mitochondria of all living cells. It also occurs in the food chain and is endogenously produced in the liver. There are conditions in which adequate production of CoQlO in the body is impaired, and in such situations supplementation with CoQ10 has been shown to be very beneficial. |
| CoQlO, being lipid soluble, follows the same pathway as that of fats for its absorption in the body. This involves emulsification in the intestine (with the help of bile salts and various lipolyases) and the formation of micelles prior to absorption. Among the other factors affecting the absorption of exogenously administered CoQlO are its particle size, degree of solubilization, and the type of food ingested with the supplement. |
| Although CoQ1O is classified as a lipid soluble substance, its degree of solubility is extremely limited. Commercially available CoQlO capsules contain either oil-based suspensions (softgels), or dry powder with silicon dioxide and talc blends (hard gels). When tested in the laboratory, these products show a total lack of dissolution according to current USP methodology. Such lack of dissolution properties are often indicative of poor absorption and bioavailability. |
| In order to improve the
dissolution profile and bioavailability of CoQl0, KAMPOYAKI RESEARCH SDN BHD
(Malaysia) has acquired an exclusive technology (formulation/process) from
BioTakenaka Pharm.Co, Japan. This novel Bio- Coenzyme Q10 purum process has provided the
key to the solubilization of CoQlO. Bio-Coenzyme Q10 purumsoftsules® based on the Bio-
Coenzyme Q10 purum formulation and process exhibit complete dissolution, which is
indicative of improved absorption/bioavailability. A human study was subsequently carried out to compare the relative bioavailability of Coenzyme Q10 purum softgels with other currently available dosage forms (softgels, tablets and capsules), and the data obtained from the study clearly demonstrate that Coenzyme Q10 purum softgel is vastly superior (about 300% higher relative bioavailability than all other dosage forms tested). |
| These data are private and unpublished and are subjected to patent pending applications April 9, 1998.(A new Coenzyme Q10 preparation with enhanced relative Bioavailability). |
| Bio-CO-ENZYME Q-10 (coupled with enzymes)(ubiquinone) |
| Description |
| Appearance: | Waxy Crystalline Powder, |
| Particle Size: | 20-60 mesh |
| Color: | White to Buff |
| Aroma: | Neutral |
| Taste: | Characteristic |
| Recognition Test: |
| Maximum absorbance of the oxidized
solution is seen at 275+/- nm, and that of reduce solution at 290+/- nm.
Full Detailed of GC methodology of purity Bio-CoEnzyme Q10 available for confirmed order of 500kg and above |
Storage: Cool,dry area; Decomposes at around 48C (118F). Comments: Bio-CoEnzyme
Q10 Orange ( Liquid Grade) for Cosmetic Formulations |
| Analysis: |
| Assay Ubiquinone: | NLT 99.5% |
| Co-Q9 (Ubiquinone homolog & enzyme*): | "0.2% Min. |
| Moisture: | NMT 0.2% |
| Ash: | NMT 0.1% |
| Heavy Metals: | NMT 20 ppm |
| Arsenic: | NMT 2 ppm |
Microbial:
| E. Coli: | Negative |
| Salmonella: | Negative |
| Germs | <100 cfu/gm Non-pathogenic |
| Yeasts/Molds | < 100 cfu/gm |
Enzyme coupling:
NAME:
NADH dehydrogenase (ubiquinone) flavoprotein 2 (24kD) H.sapiens [EC:1.6.5.3]
CLASS Metabolism; Energy Metabolism; Oxidative phosphorylation [MAP:00190]
Metabolism; Metabolism of Cofactors and Vitamins; Ubiquinone
biosynthesis [MAP:00130]
This information is presented in the belief
that it is accurate and reliable; however, no warranty, either expressed or implied and no
freedom from liability form patents, trademarks, or other limitations should be inferred.
Any data listed are averages only and are not to be considered as guarantees expressed or
implied, nor as a condition of sale.
Metabolism; Metabolism of Cofactors and Vitamins; Ubiquinone biosynthesis [MAP:00130]
The identification via chromatography column
| 1 Co-Enzyme Q9 | 2 Co-Enzyme Q10 |
Special purpose column An SE-54 type phase developed and tested for reproducible Analysis of Bio-Coenzyme Q10. (BioTakenaka Pharm).
| Phase: | bonded; poly(5% diphenyl/ 95% dimethylsiloxane) |
| Temp. Limits: | -60 deg.Cent. to 320 deg. Cent. |
| McReynolds Nos: | x’ y’ z’ u’s’ = 19 74 64 93 62 |
Length (m) d1(um) Beta
0.25mm ID Fused Silica
30 0.25 250
References:
1) B.O. Linn, A.C. Page, E.L. Wong, et al, J Am Chem Soc 1959; 81: 4007-4010.
2) F.L. Crane, Y. Hatefi, R.L. Lester, et al, Biochim Biophys Acta 1957; 25: 220- 221.
3) T. Kishi, T. Okamoto, H. Kishi, et al, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 5. Elsevier Science Publishers, Amsterdam. 1985, p. 119-123.
4) P.M. Kidd, W. Huber, F. Summerfield, et al, Coenzyme Q10: Essential Energy Carrier and Antioxidant. H.K. Biomedical Consultants, Berkeley. 1988, p. 3.
5-a) See reference 3.
5-b) K. Folkers, T. Watanabe, M. Kaji, J Mol Med 1977; 2: 431-460.
6) Y. Yamamura, In: G. Lenaz (ed.), Coenzyme Q, John Wiley & Sons, Ltd., 1985, p. 479.
7) P.H. Langsjoen, P.H. Langsjoen, K. Folkers, In: K. Folkers, G.P. Littarru, and T. Yamagami (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 6. Elsevier Science Publichers, Amsterdam. 1991, p. 241-246.
8) S. Momomura, T. Serizawa, Y. Ohtani, et al, Jpn Heart J 1991; 32: 101-110.
9) K. Folkers, P. Langsjoen, P.H. Langsjoen, Biochem Biophys Res Commun 1992; 182: 247-253.
10) A. Bertelli, G. Ronca, Int J Tissue React 1990; 12: 183-186.
11) J. Azuma, A. Sawamura, N. Awata, Jpn Circ J 1992; 56: 95-99.
12) T. Kato, S. Yoneda, T. Kako, et al, Int J Clin Pharmacol Ther Toxicol 1990; 28:123-126.
13) D. Mohr, V.W. Bowry, R. Stocker, Biochim Biophys Acta 1992; 1126: 247-254.
14) W.G. Nayler, In: Y. Yamamura, K. Folkers and Y. Ito (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 2. Elsevier / North Holland Biomedical Press Amsterdam. 1980, p. 409-425.
15) T. Kamikawa, A. Kobayashi, T. Yamashita, et al, Am J Cardiol 1985; 56: 247.
16) F. Shardt, D. Welzel, W. Scheiss, et al, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 5. Elsevier Science Publishers, Amsterdam. 1985, p. 385-394.
17) S. Nagai, Y. Miyazuki, K. Ogawa, et al, J Mol Cell Cardiol 1985; 17: 873.
18) J. Tanaka, R. Tominaga, M.D. Yoshitoshi, et al, Ann Thorac Surg 1982; 33: 145.
19) M. Sunamori, T. Okamura, J. Amano, et al, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 4. Elsevier / North Holland Biomedical Press, Amsterdam. 1984, p. 333-342.
20) Y. Iwamoto, I.L. Hansen, T.H. Porter, et al, Biochem Biophys Res Commun 1974; 58:633.
21) K. Folkers, L. Baker, P.C. Richardson, et al, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 3. Elsevier / North Holland Biomedical Press, Amsterdam. 1981, p. 399-412.
22) N. Yamanaka, T. Kato, K. Nishida, et al, In: Y.Yamamura, K. Folkers, and Y. Ito (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 2. Elsevier/ North Holland Biomedical Press, Amsterdam. 1980, P. 213-224.
23) T. Kishi, K. Makino, T. Okamoto, et al, In: Y. Yamamura, K. Folkers, and Y. Ito (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 2. Elsevier / North Holland Biomedical Press, Amsterdam. 1980, p. 139-157.
24) K. Folkers, In: G. Lenaz (ed.), Coenzyme Q, John Wiley & Sons, Ltd., New York. 1985, p. 476.
25) K. Folkers and Per Langsjoen, In: K. Folkers, K. Folkers, G.P. Littarru, and T. Yamagami (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 6. Elsevier Science Publishers, Amsterdam. 1991, p. 449-452.
26) M. Bifulco, C. Laezza, S.M. Aloj, et al, J Cell Physiol 1993; 155: 340-348.
27) R.V. Omkumar, A.S. Gaikwad, T. Ramasarma, Biochem Biophys Res Commun 1992; 184: 1280-1287.
Part 2
28) T.M. Farley, J. Scholler, K. Folkers, Biochem Biophys Res Comm 1966; 24: 299.
29) K. Folkers, J. Wolaniuk, R. Simonsen, et al, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q, vol. 5. Elsevier Science Publishers, Amsterdam. 1985, p. 353-358.
30) R. Simonsen, K. Folkers, J. Komorowski, et al, In: K. Folkers, G.P. Littarru, and T. Yamagami (eds.), Biochemical and Clinical Aspects of Coenzyme Q, vol. 6. Elsevier Science Publishers, Amsterdam. 1991, p. 363-373.
31) K. Folkers, R. Brown, W. Judy, et al, Biochem Biophys Res Comm 1993; 192: 241-245.
32) G.P. Littarru, S. Lippa, A. Oradei, et al, In: G. Lenaz, O. Barnabei, A Rabbi, M. Battino (eds.), Highlights in Ubiquinone Research, Taylor & Francis, New York. 1990, p. 220-225.
33) R. Beyer, In: K. Folkers, G.P. Littarru, and Y. Yamagami (eds.), Biochemical and Clinical Aspects of Coenzyme Q, vol. 6. Elsevier Science Publishers, Amsterdam. 1991, p. 501-509.
34) J.M.P. Vanfraechem, K. Folkers, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q, vol. 3. Elsevier/North Holland Biochemical Press, Amsterdam. 1981, p. 235.
35) P.L. Fiorella, A.M. Bargossi, G. Grossi, et al, In: K. Folkers, G.P. Littarru, and T. Yamagami (eds.), Biochemical and Clinical Aspects of Coenzyme Q, vol. 6. Elsevier Science Publishers, Amsterdam. 1991, p. 513-520.
36) P. Zeppilli, B. Merlino, A. DeLuca, et al, In: K. Folkers, G.P. Lttarru and Y. Yamagami (eds.), Biochemical and Clinical Aspects of Coenzyme Q, vol. 6. Elsevier Science Publishers, Amsterdam. 1991, p. 541-545.
37) H. Yamabe, H. Fukuzaki, In: K. Folkers, G.P. Littarru, and T. Yamagami (eds.), Biochemical and Clinical Aspects of Coenzyme Q, vol. 6. Elsevier Science Publishers, Amsterdam. 1991, p. 535-540.
38) V. Wyss, T. Lubich, G.P. Granzit, et al, In: G. Lenaz, O. Barnabei, A. Rabbi, M. Battino (eds.), Highlights in Ubiquinone Research, Taylor & Francis, New York. 1990, p. 303-306.
39) B.O. Linn, A.C. Page, E.L. Wong, et al, J Am Chem Soc 1959; 81: 4007-4010.
40) T. Kishi, H. Kishi, T. Watanabe, J Med 1976; 7: 307-321.
41) Y. Shigata, K. Izumi, H. Abe, J Vitaminol 1966; 12: 293-298.
42) S. Shizukuishi, T. Hanioka, A. Tsunemitsu, et al, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Apsects of Coenzyme Q, vol. 5. Elsevier Science Publishers, Amsterdam. 1985, p. 359-368.
43) G.P. Littarru, R. Nakamura, L. Ho, et al, Proc Natl Acad Sci 1971; 68: 2232- 2335. Part 3
44) E.G. Bliznakov, A.C. Casey, E. Premuzic, Experentia 1970; 26: 953-954.
45) E.G. Bliznakov, Proc Nat Acad Sci USA 1973; 70: 390-394.
46) E.G. Bliznakov, A.C. Casey, T. Kishi, et al, Internat J Vitam Nutr Res 1975; 45: 388-395.
47) E.G. Bliznakov, T. Watanabe, S. Saji, et al, J Med 1978; 9: 337-346.
48) G. Hogenauer, P. Mayer, J. Drews, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 3. Elsevier / North Holland Biomedical Press, Amsterdam. 1981, p. 325-334.
49) A.C. Casey, E.G. Bliznakov, Chem-Biol Interactions 1972; 5: 1-12.
50) K. Folkers, S. Shizukuishi, K. Takemura, et al, Res Commun Chem Path Pharm 1982; 38: 335-338.
51) E.G. Bliznakov, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 3. Elsevier / North Holland Biomedical Press, Amsterdam. 1981, p. 311-323.
52) P.H. Langsjoen, P.H. Langsjoen, K. Folkers, In: K. Folkers, G.P. Littarru, and T. Yamagami (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 6 Elsevier Science Publishers, Amsterdam. 1991, p. 409-415.
53) R. Stocker, V.W. Bowry, B. Frei, Proc Natl Acad Sci USA 1991; 88: 1646-1650.
54) D. Mohr, V.W. Bowry, R. Stocker, Biochim Biophys Acta 1992; 1126: 247-253.
55) Y. Hanaki, et al, N Engl J Med 1991; 325: 814-815.
56) T. Matsubara, T. Azuma, S. Yoshida, et al, In: K. Folkers, G.P Littarru, and T. Yamagami (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 6. Elsevier Science Publishers, Amsterdam. 1991, p. 159-166.
57) C. Edlund, M. Soderberg, K. Kristensson, et al, Biochem Cell Biol 1992; 70: 422- 428.
58) M. Imagawa, et al, Lancet 1992; 340: 671.
59) K. Anderson: Orphan Drugs. New York: The Linden Press / Simon & Schuster, 1983, p. 238-239.
60) T. Kishi, T. Okamoto, N. Kanamori, et al, In: K. Folkers and Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q, Vol. 3. Elsevier / North Holland Biomedical Press, Amsterdam. 1981, p. 67-70.
| Part1 | Part2 | Part3 | Co-Enzyme Q10 and The Skin |